Armata Pharmaceuticals, Inc.
ARMP NYSE
SEC CIK 921114
Follow Armata Pharmaceuticals
Weekly email: filings, results
EPS, diluted
$1.15
+255.4% vs same quarter last year
Operating cash flow
−$5.5M
−28.3% vs same quarter last year
Operating income
−$7.4M
+5.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$173.8M |
| FY24 | −$18.9M |
| FY23 | −$69M |
| FY22 | −$36.9M |
| FY21 | −$23.2M |
| FY20 | −$22.2M |
| FY19 | −$19.5M |
| FY18 | −$16.7M |
| FY17 | −$12.8M |
| FY16 | −$18.8M |
| FY15 | −$516K |
| FY14 | - |
| FY13 | −$64.6M |
| FY12 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$26.3M |
| FY24 | −$39.4M |
| FY23 | −$55.6M |
| FY22 | −$34.7M |
| FY21 | −$24.9M |
| FY20 | −$19.1M |
| FY19 | −$15.8M |
| FY18 | −$11.5M |
| FY17 | −$9.3M |
| FY16 | −$10.9M |
| FY15 | −$10M |
| FY14 | −$13.8M |
| FY13 | −$6.4M |
| FY12 | - |